Overview of US Prostate Cancer Trends in the Era of PSA Screening

  • Ruth Etzioni
  • Roman Gulati
  • Angela Mariotto
Part of the Current Clinical Urology book series (CCU)

Summary

Prostate cancer rates in the United States have changed radically over the last two decades. The introduction of prostate-specific antigen (PSA) screening impacted incidence substantially; however, in the absence of randomized clinical trials, its role in the precipitous mortality decline remains unclear. Simultaneous advances in treatment, shifting patterns of care, and changing health behaviors may also have contributed to this decline. Two veins of investigation–-ecologic and modeling studies–-provide insights into the benefits and costs of PSA screening, with the latter positioned to help design optimal intervention policies.

Key Words

PSA screening Natural experiment Will Rogers phenomenon Lead time Overdiagnosis Ecologic studies Surveillance modeling 

References

  1. 1.
    Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER\(^{\ast}\)Stat Database: Incidence–-SEER 9 Regs Limited-Use, Nov 2006 Sub (1973–2005), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on the November 2007 submission.
  2. 2.
    Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER\(^{\ast}\)Stat Database: Mortality–-All COD, Public-Use With State, Total U.S. (1969–2005), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).
  3. 3.
    Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). Prevalence database: “US Estimated Complete Prevalence Counts on 1/1/2005”. National Cancer Institute, DCCPS, Surveillance Research Program, Statistical Research and Applications Branch, released April 2008, based on the November 2007 SEER data submission.
  4. 4.
    Mariotto, A., Etzioni, R., Krapcho, M., and Feuer, E. J. (2007) Reconstructing prostate-specific antigen (PSA) testing patterns among black and white men in the US from Medicare claims and the National Health Interview Survey Cancer 109, 1877–86.CrossRefPubMedGoogle Scholar
  5. 5.
    Cooperberg, M. R., Grossfeld, G. D., Lubeck, D. P., and Carroll, P. R. (2003) National practice patterns and time trends in androgen ablation for localized prostate cancer J Natl Cancer Inst 95, 981–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Zeliadt, S., Potosky, A., Etzioni, R., Ramsey, S., and Penson, D. (2004) Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999 Urology 64, 1171–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Etzioni, R., Gulati, R., Falcon, S., and Penson, D. (2008) Impact of PSA screening on the incidence of advanced stage prostate cancer in the US: A surveillance modeling approach Med Decis Making 28(3), 323–31.CrossRefPubMedGoogle Scholar
  8. 8.
    Albertsen, P. C., Hanley, J. A., Barrows, G. H., Penson, D. F., Kowalczyk, P. D., Sanders, M. M., and Fine, J. (2005) Prostate cancer and the Will Rogers phenomenon J Natl Cancer Inst 97, 1248–53.CrossRefPubMedGoogle Scholar
  9. 9.
    Thompson, I. M., Canby-Hagino, E., and Lucia, M. S. (2005) Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor J Natl Cancer Inst 97, 1236–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Feuer, E. J., and Wun, L. M. (1992) How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization? A dynamic population model approach Am J Epidemiol 136, 1423–36.PubMedGoogle Scholar
  11. 11.
    Etzioni, R., Penson, D. F., Legler, J. M., Di Tommaso, D., Boer, R., Gann, P. H., and Feuer, E. J. (2002) Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends J Natl Cancer Inst 94, 981–90.PubMedGoogle Scholar
  12. 12.
    Tsodikov, A., Szabo, A., and Wegelin, J. (2006) A population model of prostate cancer incidence Stat Med 25, 2846–66.CrossRefPubMedGoogle Scholar
  13. 13.
    Telesca, D., Etzioni, R., and Gulati, R. (2008) Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence Trends Biometrics 64, 10–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Draisma, G., Etzioni, R., Tsodikov, A., Mariotto, A., Wever, E., Gulati, R., Feuer, E., and De Koning, H. J. (2008, Submitted for publication) Reconciling Differing Estimates of Lead Time and Overdiagnosis Due to PSA Screening: Results from the Cancer Intervention and Surveillance Modeling Network J Natl Cancer Inst.Google Scholar
  15. 15.
    Draisma, G., Boer, R., Otto, S. J., Van Der Cruijsen, I. W., Damhuis, R. A., Schröder, F. H., and De Koning, H. J. (2003) Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95, 868–78.CrossRefPubMedGoogle Scholar
  16. 16.
    Weiss, N. S., and Rossing, M. A. (1996) Healthy screened bias in epidemiologic studies of cancer incidence Epidemiology 7, 319–22.PubMedGoogle Scholar
  17. 17.
    Lu-Yao, G., Albertsen, P. C., Stanford, J. L., Stukel, T. A., Walker-Corkery, E. S., and Barry, M. J. (2002) Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut BMJ 325, 740.CrossRefPubMedGoogle Scholar
  18. 18.
    Shaw, P. A., Etzioni, R., Zeliadt, S. B., Mariotto, A., Karnofski, K., Penson, D. F., Weiss, N. S., and Feuer, E. J. (2004) An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States Am J Epidemiol 160, 1059–69.CrossRefPubMedGoogle Scholar
  19. 19.
    Zeliadt, S. B., Potosky, A. L., Etzioni, R., Ramsey, S. D., and Penson, D. F. (2004) Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999 Urology 64, 1171–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R. O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Mattelaer, J., Lopez Torecilla, J., Pfeffer, J. R., Lino Cutajar, C., Zurlo, A., and Pierart, M. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360, 103–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Albertsen, P. C. (2003) The prostate cancer conundrum J Natl Cancer Inst 95, 930–1.CrossRefPubMedGoogle Scholar
  22. 22.
    Etzioni, R., Legler, J. M., Feuer, E. J., Merrill, R. M., Cronin, K. A., and Hankey, B. F. (1999) Cancer surveillance series: Interpreting trends in prostate cancer–-Part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality J Natl Cancer Inst 91, 1033–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Etzioni, R., Tsodikov, A., Mariotto, A., Szabo, A., Falcon, S., Wegelin, J., Ditommaso, D., Karnofski, K., Gulati, R., Penson, D. F., and Feuer, E. (2008) Quantifying the role of PSA screening in the US prostate cancer mortality decline Cancer Causes Control 19, 175–81.CrossRefPubMedGoogle Scholar
  24. 24.
    Feuer, E. J., Mariotto, A., and Merrill, R. (2002) Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates Cancer 95, 870–80.CrossRefPubMedGoogle Scholar
  25. 25.
    Cooperberg, M. R., Lubeck, D. P., Meng, M. V., Mehta, S. S., and Carroll, P. R. (2004) The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management J Clin Oncol 22, 2141–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Kristal, A. R., and Gong, Z. (2007) Obesity and prostate cancer mortality Future Oncol 3, 557–67.CrossRefPubMedGoogle Scholar
  27. 27.
    Gong, Z., Agalliu, I., Lin, D. W., Stanford, J. L., and Kristal, A. R. (2007) Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men Cancer 109, 1192–202.CrossRefPubMedGoogle Scholar
  28. 28.
    Gong, Z., Neuhouser, M. L., Goodman, P. J., Albanes, D., Chi, C., Hsing, A. W., Lippman, S. M., Platz, E. A., Pollak, M. N., Thompson, I. M., and Kristal, A. R. (2006) Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial Cancer Epidemiol Biomarkers Prev 15, 1977–83.CrossRefPubMedGoogle Scholar
  29. 29.
    Etzioni, R., and Feuer, E. (In Press) Learning from international studies of prostate cancer mortality: A cautionary tale Lancet Oncol . Google Scholar
  30. 30.
    Kim, H. J., Fay, M. P., Feuer, E. J., and Midthune, D. N. (2000) Permutation tests for joinpoint regression with applications to cancer rates Stat Med 19, 335–51.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Ruth Etzioni
    • 1
  • Roman Gulati
    • 2
  • Angela Mariotto
    • 3
  1. 1.Fred Hutchinson Cancer Research CenterSeattleUSA
  2. 2.Fred Hutchinson Cancer Research CenterSeattleUSA
  3. 3.Division of Cancer Control and Population SciencesNational Cancer InstituteBethesdaUSA

Personalised recommendations